Deep Track Capital's Strategic Acquisition of Century Therapeutics Shares: A Potential Value Trap

Deep Track Capital has acquired 13.49 million shares of Century Therapeutics at $1.77 per share. This marks a new holding in the firm's portfolio, reflecting confidence in Century Therapeutics' potential despite current financial challenges. The acquisition represents 0.66% of Deep Track Capital's portfolio and 7.34% of Century Therapeutics' total shares. Century Therapeutics has a market capitalization of $178.31 million and a current stock price of $2.04. Despite a 15.25% gain since the transaction, the stock remains undervalued with a GF Value of $43.03.